ScreenerHero
IPNIpsen S.A.
EPA · FR · Healthcare · Drug Manufacturers - Specialty & Generic · ipsen.com
163.80EUR0.00%Mkt Cap: 14.67B $P/E: 26.48

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Soma…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap14.67B $
Enterprise Value13.55B $
Revenue (TTM)4.66B $
Gross Profit3.45B $
Net Income (TTM)482.07M $
Revenue/Share56.52 USD
Last Price163.80 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5.5K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)26.48
P/E (Forward)11.76
PEG0.64
EV/EBITDA8.57
EV/Revenue2.90
P/S3.15
P/B2.86
EPS (TTM)6.17
EPS (Forward)13.90
52W Range
109.9084% of range174.00
52W High174.00 EUR
52W Low109.90 EUR
Profitability
Gross Margin80.89%
Oper. Margin28.49%
EBITDA Margin33.88%
Profit Margin11.29%
ROE10.23%
ROA6.39%
Growth
Revenue Growth18.70%
Earnings Growth21.50%
Cash Flow & Leverage
Operating CF1.24B $
CapEx (TTM)357.28M $
FCF Margin23.16%
FCF Yield7.36%
Net Debt-1.10B $
Net Debt/EBITDA-0.69
Balance Sheet
Debt/Equity0.20
Current Ratio1.97
Quick Ratio1.77
Book Value/Sh57.15 EUR
Cash/Share23.91 EUR
Dividends
Fwd Div Rate1.600 EUR
Trail. Div Rate1.600 EUR
Div. Yield0.97%
5Y Avg Yield1.11%
Payout Ratio25.89%
Ex-Div DateJun 3, 2026
Pay Date—
Analyst Consensus
Rating2.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)167.07 EUR
Upside (mean)+2.0%
Target Range130.00 EUR – 235.00 EUR
€130.00+2.0% to mean€235.00
# Analysts15
Ownership
Shares Out.82.61M
Float29.97M
Insiders57.64%
Institutions21.33%
Technical
SMA 50161.23 (+1.6%)
SMA 200149.61 (+9.5%)
Beta0.32
S&P 52W Chg18.16%
Avg Vol (30d)49.89K
Avg Vol (10d)93.89K
Technical Indicators
RSI (14)54.3
MACD0.3215
MACD Signal-0.5019
MACD Hist.+0.8235
BB Upper168.04 EUR
BB Middle159.84 EUR
BB Lower151.64 EUR
BB Width10.26%
ATR (14)4.775 EUR
Vol Ratio (20d)0.60x